β-Arrestin2 is a critical component of the GPCR–eNOS signalosome
- 13 May 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (21), 11483-11492
- https://doi.org/10.1073/pnas.1922608117
Abstract
Endothelial cell nitric oxide (NO) synthase (eNOS), the enzyme responsible for synthesis of NO in endothelial cells, is regulated by complex posttranslational mechanisms. Sinusoidal portal hypertension, a disorder characterized by liver sinusoidal endothelial cell (SEC) injury with resultant reduced eNOS activity and NO production within the liver, has been associated with defects in eNOS protein–protein interactions and posttranslational modifications. We and others have previously identified novel eNOS interactors, including G protein-coupled receptor (GPCR) kinase interactor 1 (GIT1), which we found to play an unexpected stimulatory role in GPCR-mediated eNOS signaling. Here we report that β-arrestin 2 (β-Arr2), a canonical GPCR signaling partner, localizes in SECs with eNOS in a GIT1/eNOS/NO signaling module. Most importantly, we show that β-Arr2 stimulates eNOS activity, and that β-Arr2 expression is reduced and formation of the GIT1/eNOS/NO signaling module is interrupted during liver injury. In β-Arr2–deficient mice, bile duct ligation injury (BDL) led to significantly reduced eNOS activity and to a dramatic increase in portal hypertension compared to BDL in wild-type mice. Overexpression of β-Arr2 in injured or β-Arr2–deficient SECs rescued eNOS function by increasing eNOS complex formation and NO production. We also found that β-Arr2–mediated GIT1/eNOS complex formation is dependent on Erk1/2 and Src, two kinases known to interact with and be activated by β-Arr2 in response to GCPR activation. Our data emphasize that β-Arr2 is an integral component of the GIT1/eNOS/NO signaling pathway and have implications for the pathogenesis of sinusoidal portal hypertension.Keywords
Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK 113159)
This publication has 72 references indexed in Scilit:
- Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapyFrontiers in Physiology, 2013
- Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptorsProceedings of the National Academy of Sciences of the United States of America, 2012
- G-protein-coupled Receptor Kinase Interactor-1 (GIT1) Is a New Endothelial Nitric-oxide Synthase (eNOS) Interactor with Functional Effects on Vascular HomeostasisPublished by Elsevier BV ,2012
- Ubiquitin-Mediated Regulation of Endocytosis by Proteins of the Arrestin FamilyBiochemistry Research International, 2012
- Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in miceJCI Insight, 2011
- β-Arrestin–Biased Agonism of the Angiotensin Receptor Induced by Mechanical StressScience Signaling, 2010
- GIT1 is a novel MEK1–ERK1/2 scaffold that localizes to focal adhesionsCell Biology International, 2010
- S-Nitrosylation of β-Arrestin Regulates β-Adrenergic Receptor TraffickingMolecular Cell, 2008
- β-Arrestin 2 Expression Determines the Transcriptional Response to Lysophosphatidic Acid Stimulation in Murine Embryo FibroblastsPublished by Elsevier BV ,2005
- An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and BehaviorCell, 2005